Cargando…
Targets and emerging therapies for schizophrenia /
Although the dopamine hypothesis has been the cornerstone of schizophrenia therapeutics, it is clear that dopamine-based approaches do not treat all aspects of the disease. Moreover, many schizophrenia patients fail to respond to current antipsychotics. Integrating chemistry, biology, and pharmacolo...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Hoboken, New Jersey :
John Wiley & Sons,
©2012.
|
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000 a 4500 | ||
|---|---|---|---|
| 001 | EBOOKCENTRAL_ocn769289644 | ||
| 003 | OCoLC | ||
| 005 | 20240329122006.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 111222s2012 nju ob 001 0 eng | ||
| 010 | |a 2011052987 | ||
| 040 | |a DLC |b eng |e pn |c DLC |d EBLCP |d IDEBK |d N$T |d DG1 |d YDXCP |d E7B |d STF |d COO |d UBY |d NLGGC |d OCLCF |d OCLCQ |d OCLCO |d OCLCQ |d OCLCO |d OCLCQ |d OCLCO |d DEBBG |d AZK |d OCLCQ |d LOA |d OCLCO |d OCLCA |d DG1 |d COCUF |d CHVBK |d OCLCO |d MERER |d OCLCO |d MOR |d LIP |d OCLCO |d PIFAG |d ZCU |d OCLCO |d OCLCQ |d MERUC |d OCLCO |d OCLCQ |d OCLCO |d OCLCA |d U3W |d OCLCO |d OCLCQ |d WRM |d NRAMU |d ICG |d VTS |d OCLCQ |d VT2 |d OCLCO |d AU@ |d OCLCO |d OCLCQ |d WYU |d OCLCO |d CUY |d OCLCO |d OCLCA |d UWO |d TKN |d OCLCO |d OCLCQ |d OCLCO |d OCLCQ |d DKC |d OCLCO |d OCLCQ |d NOC |d OCLCQ |d OCLCA |d OCLCQ |d UKCRE |d OCLCO |d OCLCQ |d OCLCO |d OCLCL | ||
| 019 | |a 795894798 |a 798698963 |a 808669946 |a 817089457 |a 961501567 |a 962591718 |a 966253987 |a 974754734 |a 974870930 |a 988532949 |a 991925662 |a 1014221409 |a 1017999707 |a 1037711189 |a 1038647640 |a 1038697262 |a 1041911588 |a 1045517306 |a 1067170848 |a 1089032075 |a 1119011936 |a 1148117437 |a 1153553655 |a 1257357565 | ||
| 020 | |a 9781118309407 |q (epub) | ||
| 020 | |a 1118309405 |q (epub) | ||
| 020 | |a 9781118309384 |q (epdf) | ||
| 020 | |a 1118309383 |q (epdf) | ||
| 020 | |a 9781118309391 |q (emobi) | ||
| 020 | |a 1118309391 |q (emobi) | ||
| 020 | |a 9781118309421 |q (electronic bk.) | ||
| 020 | |a 1118309421 |q (electronic bk.) | ||
| 020 | |a 1280699310 | ||
| 020 | |a 9781280699313 | ||
| 020 | |a 0470322829 |q (cloth) | ||
| 020 | |a 9780470322826 |q (cloth) | ||
| 020 | |z 9780470322826 |q (cloth) | ||
| 029 | 1 | |a AU@ |b 000048329675 | |
| 029 | 1 | |a CHNEW |b 000938814 | |
| 029 | 1 | |a CHVBK |b 480190984 | |
| 029 | 1 | |a DEBBG |b BV043393917 | |
| 029 | 1 | |a DEBBG |b BV044161946 | |
| 029 | 1 | |a DEBSZ |b 485011425 | |
| 029 | 1 | |a NZ1 |b 14693634 | |
| 029 | 1 | |a AU@ |b 000073064437 | |
| 035 | |a (OCoLC)769289644 |z (OCoLC)795894798 |z (OCoLC)798698963 |z (OCoLC)808669946 |z (OCoLC)817089457 |z (OCoLC)961501567 |z (OCoLC)962591718 |z (OCoLC)966253987 |z (OCoLC)974754734 |z (OCoLC)974870930 |z (OCoLC)988532949 |z (OCoLC)991925662 |z (OCoLC)1014221409 |z (OCoLC)1017999707 |z (OCoLC)1037711189 |z (OCoLC)1038647640 |z (OCoLC)1038697262 |z (OCoLC)1041911588 |z (OCoLC)1045517306 |z (OCoLC)1067170848 |z (OCoLC)1089032075 |z (OCoLC)1119011936 |z (OCoLC)1148117437 |z (OCoLC)1153553655 |z (OCoLC)1257357565 | ||
| 037 | |a 10.1002/9781118309421 |b Wiley InterScience |n http://www3.interscience.wiley.com | ||
| 042 | |a pcc | ||
| 050 | 0 | 0 | |a RC514 |
| 060 | 4 | |a WM 203 | |
| 072 | 7 | |a PSY |x 022050 |2 bisacsh | |
| 082 | 0 | 0 | |a 616.89/8061 |2 23 |
| 049 | |a UAMI | ||
| 245 | 0 | 0 | |a Targets and emerging therapies for schizophrenia / |c edited by Jeffrey S. Albert, Michael W. Wood. |
| 260 | |a Hoboken, New Jersey : |b John Wiley & Sons, |c ©2012. | ||
| 300 | |a 1 online resource | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a data file |2 rda | ||
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 0 | |a Dopaminergic hypothesis of schizophrenia : a historical perspective / Aurelija Jucaite and Svante Nyberg -- Dopamine D2/D3 partial agonists as antipsychotics / Philip G. Strange -- D1/D5 dopamine agonists as pharmacotherapy for schizophrenia / Kevin N. Boyd and Richard B. Mailman -- PDE inhibitors as a novel therapeutic approach for schizophrenia / Judith A. Siuciak and William J. Pitts -- Glutamatergic synaptic dysregulation in schizophrenia / Joseph T. Coyle, Alo Basu, and Michael Benneyworth -- Metabotropic glutamate 2/3 receptor agonists and positive allosteric modulators of metabotropic glutamate receptor 2 as novel agents for the treatment of schizophrenia / Gerard J. Marek [and others] -- AMPA receptor positive modulators / John A. Morrow, John K.F. Maclean, and Craig Jamieson -- Progress in the exploration and development of GlyT1 inhibitors for schizophrenia / Jeffrey S. Albert and Michael W. Wood -- Combined dopamine D2 and 5-hydroxytryptamine (5-HT)1a receptor strategies for the treatment of schizophrenia, a pharmacological and chemical perspective / Andrew C. Mccreary, Roelof W. Feenstra, and Caitlin A. Jones -- 5-HT2C and 5-HT6 receptor targeted emerging approaches in schizophrenia / Sharon Rosenzweig-Lipson [and others] -- The cholinergic hypothesis : an introduction to the hypothesis and a short history / Joseph I. Friedman, Isabella Kanellopoulou, and Vladan Novakovic -- À7 nicotinic acetylcholine receptors in the treatment of schizophrenia / Mihály Hajós, and Bruce N. Rogers -- Muscarinic acetylcholine receptors as novel targets for the development of therapeutics for schizophrenia / Christian C. Felder [and others] -- Will modulation of neuropeptide receptors produce the next generation of antipsychotic drugs? : a focus on the neurokinin and neurotensin systems / Lee A. Dawson, Paul W. Smith, and Jeannette M. Watson -- GABA and schizophrenia / John H. Kehne and George D. Maynard. | |
| 588 | 0 | |a Print version record and CIP data provided by publisher. | |
| 520 | |a Although the dopamine hypothesis has been the cornerstone of schizophrenia therapeutics, it is clear that dopamine-based approaches do not treat all aspects of the disease. Moreover, many schizophrenia patients fail to respond to current antipsychotics. Integrating chemistry, biology, and pharmacology, this book explores emerging directions in pharmaceutical research for drug targeting and discovery in order to find more effective treatments for schizophrenia, one of the most serious and widespread psychiatric diseases. | ||
| 590 | |a ProQuest Ebook Central |b Ebook Central Academic Complete | ||
| 650 | 0 | |a Schizophrenia |x Treatment. | |
| 650 | 2 | |a Schizophrenia |x drug therapy | |
| 650 | 2 | |a Drug Delivery Systems | |
| 650 | 6 | |a Schizophrénie |x Traitement. | |
| 650 | 7 | |a PSYCHOLOGY |x Psychopathology |x Schizophrenia. |2 bisacsh | |
| 650 | 7 | |a Schizophrenia |x Treatment |2 fast | |
| 700 | 1 | |a Albert, Jeffrey S. | |
| 700 | 1 | |a Wood, Michael W. |q (Michael William), |d 1961- |1 https://id.oclc.org/worldcat/entity/E39PCjwGdjk4TFcMpcpKxkHfRq | |
| 776 | 0 | 8 | |i Print version: |t Targets and emerging therapies for schizophrenia. |d Hoboken, N.J. : John Wiley & Sons, ©2012 |z 9780470322826 |w (DLC) 2011051091 |
| 856 | 4 | 0 | |u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=843663 |z Texto completo |
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL843663 | ||
| 938 | |a ebrary |b EBRY |n ebr10580248 | ||
| 938 | |a EBSCOhost |b EBSC |n 462274 | ||
| 938 | |a ProQuest MyiLibrary Digital eBook Collection |b IDEB |n 367629 | ||
| 938 | |a YBP Library Services |b YANK |n 7641480 | ||
| 938 | |a YBP Library Services |b YANK |n 7293100 | ||
| 938 | |a YBP Library Services |b YANK |n 12671943 | ||
| 994 | |a 92 |b IZTAP | ||